 |
70 Diseases |  |
70 Trials |
|
70 Trials |  |
2588 News |  |
| «12...42434445464748495051525354» |
- ||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment closed, Surgery: MISTIE III: Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III (clinicaltrials.gov) - Aug 22, 2017
P3, N=500, Active, not recruiting, Sponsor: Johns Hopkins University
Recruiting --> Active, not recruiting
- | Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment closed, Enrollment change: Efficacy and Safety of MRI-based Thrombolysis in Wake-up Stroke (clinicaltrials.gov) - Jul 19, 2017
P3, N=501, Active, not recruiting, Sponsor: Universitätsklinikum Hamburg-Eppendorf
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=800 --> 501
- | Pulmozyme (dornase alfa) / Roche, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
New P4 trial: Fibrinolytic Therapy Versus Medical Thoracoscopy (clinicaltrials.gov) - Jul 11, 2017
P4, N=80, Not yet recruiting, Sponsor: University of Florida
- | Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
New P3 trial: THEIA: A Phase III Randomized, Blind, Double Dummy, Multicenter Study Assessing the Efficacy and Safety of IV THrombolysis (Alteplase) in Patients With acutE Central retInal Artery Occlusion (clinicaltrials.gov) - Jun 22, 2017
P3, N=70, Not yet recruiting, Sponsor: Nantes University Hospital
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment change: EXTEND-IA TNK: Tenecteplase Versus Alteplase Before Endovascular Therapy for Ischemic Stroke (clinicaltrials.gov) - Jun 21, 2017
P2, N=202, Recruiting, Sponsor: Neuroscience Trials Australia
Recruiting --> Active, not recruiting | N=800 --> 501 N=64 --> 202
- |||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial completion, Trial primary completion date: A Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients (clinicaltrials.gov) - Jun 15, 2017
P2a, N=88, Completed, Sponsor: Lee Schwamm
N=64 --> 202 Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Jan 2016
- | Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
New P3 trial: FIVHeMA: Intraventricular Fibrinolysis for Aneurysmal Subarachnoid Hemorrhage. (clinicaltrials.gov) - Jun 15, 2017
P3, N=440, Not yet recruiting, Sponsor: University Hospital, Caen
- | Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Delays in Door-to-Needle Times and Their Impact on Treatment Time and Outcomes in Get With The Guidelines-Stroke. (Pubmed Central) - May 31, 2017
Hospital and eligibility delays such as delay diagnosis and inability to determine eligibility were associated with longer door-to-needle times. Improved stroke recognition and management of acute comorbidities may help to reduce door-to-needle times.
- |||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment open: ERUPTE: A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary Embolism (clinicaltrials.gov) - May 30, 2017
P2a, N=108, Recruiting, Sponsor: Tasly Pharmaceuticals, Inc.
Improved stroke recognition and management of acute comorbidities may help to reduce door-to-needle times. Not yet recruiting --> Recruiting
- | Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Treatment Patterns and Short-Term Outcomes in Ischemic Stroke in Pregnancy or Postpartum. (Pubmed Central) - May 27, 2017
Using data from the Get With the Guidelines-Stroke Registry to assemble the largest cohort of pregnant or postpartum ischemic stroke patients who had been treated with reperfusion therapy, we observed that pregnant or postpartum women had similarly favorable short-term outcomes and equal rates of total reperfusion therapy to nonpregnant women, despite lower rates of intravenous tissue plasminogen activator use. Future studies should identify the characteristics of pregnant and postpartum ischemic stroke patients who are most likely to safely benefit from reperfusion therapy.
- | Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial primary completion date: Efficacy and Safety of MRI-based Thrombolysis in Wake-up Stroke (clinicaltrials.gov) - May 22, 2017
P3, N=800, Recruiting, Sponsor: Universitätsklinikum Hamburg-Eppendorf
Future studies should identify the characteristics of pregnant and postpartum ischemic stroke patients who are most likely to safely benefit from reperfusion therapy. Trial primary completion date: Dec 2016 --> Mar 2018
- |||||||||| Fortelyzin (recombinant staphylokinase) / Supergene
New P3 trial: Single Bolus Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase in Patients With AIS (clinicaltrials.gov) - May 12, 2017
P3, N=336, Recruiting, Sponsor: Supergene, LLC
- | Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial termination: PRISMS: A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke (clinicaltrials.gov) - May 10, 2017
P3, N=313, Terminated, Sponsor: Genentech, Inc.
Trial primary completion date: Dec 2016 --> Mar 2018 Active, not recruiting --> Terminated; The study was terminated due to slow enrollment.
- | Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial suspension, Trial primary completion date: Safety and Efficacy of the Use of Tissue Plasminogen Activator (tPA) in Intra-Abdominal Collections in Children - A Prospective Study (clinicaltrials.gov) - May 5, 2017
P3, N=50, Suspended, Sponsor: The Hospital for Sick Children
Active, not recruiting --> Terminated; The study was terminated due to slow enrollment. Recruiting --> Suspended | Trial primary completion date: Dec 2016 --> Dec 2017
- | Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial primary completion date: Thrombolysis in Ischemic Spinal Cord Stroke (clinicaltrials.gov) - Apr 13, 2017
P2, N=12, Active, not recruiting, Sponsor: Rabin Medical Center
Recruiting --> Suspended | Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Oct 2017 --> Oct 2018
- ||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
New P2a trial: ERUPTE: A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary Embolism (clinicaltrials.gov) - Apr 11, 2017
P2a, N=108, Not yet recruiting, Sponsor: Tasly Pharmaceuticals, Inc.
- | Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial primary completion date: THrombolysis for Acute Wake-up and Unclear-onset Strokes With Alteplase at 0.6 mg/kg Trial (THAWS) (clinicaltrials.gov) - Apr 7, 2017
P3, N=300, Recruiting, Sponsor: National Cerebral and Cardiovascular Center
Trial primary completion date: Oct 2017 --> Oct 2018 Trial primary completion date: Dec 2017 --> Dec 2019
- ||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial completion: ATTRACT: Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis (clinicaltrials.gov) - Apr 4, 2017
P3, N=692, Completed, Sponsor: Washington University School of Medicine
Trial primary completion date: Dec 2017 --> Dec 2019 Active, not recruiting --> Completed
- | Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment closed, Enrollment change, Trial primary completion date: Enhancing Donated After Cardiac Death (DCD) Utilization With Thrombolytic Therapy (clinicaltrials.gov) - Mar 28, 2017
P=N/A, N=50, Active, not recruiting, Sponsor: The Cleveland Clinic
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=135 --> 50 | Trial primary completion date: May 2014 --> Dec 2017
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial completion: THE NOR-TEST STUDY: Study of Tenecteplase Versus Alteplase for Thrombolysis (Clot Dissolving) in Acute Ischemic Stroke (clinicaltrials.gov) - Mar 28, 2017
P3, N=1050, Completed, Sponsor: Lars Thomassen
Recruiting --> Active, not recruiting | N=135 --> 50 | Trial primary completion date: May 2014 --> Dec 2017 Recruiting --> Completed
- || Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment closed, Enrollment change: ACCESS PTS: Treatment of Chronic Deep Vein Thrombosis (DVT) and Post-Thrombotic Syndrome (PTS) With the EkoSonic® Endovascular System (clinicaltrials.gov) - Mar 21, 2017
P=N/A, N=113, Active, not recruiting, Sponsor: EKOS Corporation
Recruiting --> Completed Recruiting --> Active, not recruiting | N=200 --> 113
- ||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment closed, Enrollment change: PRISMS: A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke (clinicaltrials.gov) - Feb 23, 2017
P3, N=313, Active, not recruiting, Sponsor: Genentech, Inc.
Recruiting --> Active, not recruiting | N=200 --> 113 Terminated --> Active, not recruiting | N=948 --> 313
- | Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial termination, Trial primary completion date: PRISMS: A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke (clinicaltrials.gov) - Feb 20, 2017
P3, N=948, Terminated, Sponsor: Genentech, Inc.
Terminated --> Active, not recruiting | N=948 --> 313 Recruiting --> Terminated | Trial primary completion date: May 2018 --> Apr 2017; The study was terminated due to slow enrollment.
- Pulmozyme (dornase alfa) / Roche, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial primary completion date: Intrapleural DNase and Tissue Plasminogen Activator in Pediatric Empyema (DTPA Trial) (clinicaltrials.gov) - Feb 15, 2017
P3, N=92, Recruiting, Sponsor: The Hospital for Sick Children
Recruiting --> Terminated | Trial primary completion date: May 2018 --> Apr 2017; The study was terminated due to slow enrollment. Trial primary completion date: Dec 2016 --> Dec 2017
- Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment change, Trial termination: TOACT: Thrombolysis or Anticoagulation for Cerebral Venous Thrombosis (clinicaltrials.gov) - Feb 14, 2017
P2/3, N=67, Terminated, Sponsor: Jan Stam, MD, PhD
Trial primary completion date: Dec 2016 --> Dec 2017 N=164 --> 67 | Recruiting --> Terminated
- |||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment open: Safety and Efficacy of Alteplase When Administered in Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4.5 Hours After Stroke Onset (clinicaltrials.gov) - Dec 19, 2016
P3, N=120, Recruiting, Sponsor: Boehringer Ingelheim
N=164 --> 67 | Recruiting --> Terminated Not yet recruiting --> Recruiting
- | Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment change, Trial primary completion date: Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED) (clinicaltrials.gov) - Dec 13, 2016
P3, N=4700, Recruiting, Sponsor: The George Institute
Not yet recruiting --> Recruiting N=3300 --> 4700 | Trial primary completion date: Dec 2016 --> Dec 2018
- ||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial initiation date, Trial primary completion date: PHLO: Pediatric High-Risk Deep Venous Thrombosis Lytic Outcomes Trial (clinicaltrials.gov) - Nov 30, 2016
P3, N=270, Not yet recruiting, Sponsor: University of Colorado, Denver
N=3300 --> 4700 | Trial primary completion date: Dec 2016 --> Dec 2018 Initiation date: Oct 2016 --> Jul 2017 | Trial primary completion date: Apr 2021 --> Apr 2022
- Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial initiation date: INTRECIS: Intravenous Thrombolysis Registry for Chinese Ischemic Stroke Within 4.5 h Onset (clinicaltrials.gov) - Nov 23, 2016
P=N/A, N=3000, Not yet recruiting, Sponsor: General Hospital of Shenyang Military Region
Initiation date: Oct 2016 --> Jul 2017 | Trial primary completion date: Apr 2021 --> Apr 2022 Initiation date: Aug 2016 --> Dec 2016
- | Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
New P2 trial: FAMTAIS: Combinating Fingolimod With Alteplase Bridging With Mechanical Thrombectomy in Acute Ischemic Stroke (clinicaltrials.gov) - Nov 7, 2016
P2, N=96, Not yet recruiting, Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
- Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Clinical: PLATyPuS: Inhaled Tissue Plasminogen Activator for Acute Plastic Bronchitis (clinicaltrials.gov) - Oct 25, 2016
P2, N=24, Not yet recruiting, Sponsor: University of Michigan
Initiation date: Aug 2016 --> Dec 2016 Initiation date: Nov 2016 --> Jun 2017 | Trial primary completion date: Dec 2020 --> Aug 2021
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
New P3 trial: Safety and Efficacy of Alteplase When Administered in Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4.5 Hours After Stroke Onset (clinicaltrials.gov) - Oct 12, 2016
P3, N=120, Not yet recruiting, Sponsor: Boehringer Ingelheim
- |||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial primary completion date: ATTRACT: Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis (clinicaltrials.gov) - Oct 11, 2016
P3, N=692, Active, not recruiting, Sponsor: Washington University School of Medicine
Initiation date: Nov 2016 --> Jun 2017 | Trial primary completion date: Dec 2020 --> Aug 2021 Trial primary completion date: May 2016 --> Jan 2017
- Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment change, Trial withdrawal: ACSSLAP: Acute Coronary Syndrome Sri Lanka Audit Project (clinicaltrials.gov) - Oct 11, 2016
P=N/A, N=0, Withdrawn, Sponsor: University of Colombo
Trial primary completion date: May 2016 --> Jan 2017 N=2380 --> 0 | Completed --> Withdrawn
- | Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment open: Optimal Coronary Flow After PCI for Myocardial Infarction - a Pilot Study (clinicaltrials.gov) - Oct 9, 2016
P3, N=80, Recruiting, Sponsor: Vastra Gotaland Region
N=2380 --> 0 | Completed --> Withdrawn Not yet recruiting --> Recruiting
- Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial primary completion date: THrombolysis for Acute Wake-up and Unclear-onset Strokes With Alteplase at 0.6 mg/kg Trial (THAWS) (clinicaltrials.gov) - Sep 26, 2016
P3, N=300, Recruiting, Sponsor: National Cerebral and Cardiovascular Center
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2016 --> Dec 2017
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Trial initiation date, Trial primary completion date, Head-to-Head: DIVA: Superiority of Rt-PA + Tenecteplase in Comparison With Rt-PA Only in Proximal Middle Cerebral Artery Occlusion (clinicaltrials.gov) - Sep 23, 2016
P2, N=60, Not yet recruiting, Sponsor: University Hospital Center of Martinique
Trial primary completion date: Dec 2016 --> Dec 2017 Initiation date: Apr 2015 --> Nov 2016 | Trial primary completion date: Dec 2015 --> Dec 2017
- Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial primary completion date: EXTEND (International): Extending the Time for Thrombolysis in Emergency Neurological Deficits (International) (clinicaltrials.gov) - Sep 22, 2016
P3, N=200, Recruiting, Sponsor: Neuroscience Trials Australia
Initiation date: Apr 2015 --> Nov 2016 | Trial primary completion date: Dec 2015 --> Dec 2017 Trial primary completion date: Dec 2015 --> Dec 2017
- Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial primary completion date: Extending the Time for Thrombolysis in Emergency Neurological Deficits (clinicaltrials.gov) - Sep 22, 2016
P3, N=400, Recruiting, Sponsor: Neuroscience Trials Australia
Trial primary completion date: Dec 2015 --> Dec 2017 Trial primary completion date: Dec 2015 --> Dec 2017
- || Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
New P3 trial: Optimal Coronary Flow After PCI for Myocardial Infarction - a Pilot Study (clinicaltrials.gov) - Sep 9, 2016
P3, N=80, Not yet recruiting, Sponsor: Vastra Gotaland Region
- Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
New trial: ACSSLAP: Acute Coronary Syndrome Sri Lanka Audit Project (clinicaltrials.gov) - Sep 8, 2016
P=N/A, N=2380, Completed, Sponsor: University of Colombo
- Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
New trial: INTRECIS: Intravenous Thrombolysis Registry for Chinese Ischemic Stroke Within 4.5 h Onset (clinicaltrials.gov) - Aug 3, 2016
P=N/A, N=3000, Not yet recruiting, Sponsor: General Hospital of Shenyang Military Region
- | Meforex (recombinant human TNK tissue-type plasminogen activator) / CSPC Pharma
New P4 trial, Head-to-Head: The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute STEMI (clinicaltrials.gov) - Jul 18, 2016
P4, N=6200, Active, not recruiting, Sponsor: Guangzhou Recomgen Biotech Co., Ltd.
- || TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
New P3 trial: ATTEST2: Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (clinicaltrials.gov) - Jun 27, 2016
P3, N=1870, Not yet recruiting, Sponsor: NHS Greater Glasgow and Clyde
- Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment open, Phase classification: Trial to Compare 1.0 Versus 2.0 mg Alteplase (tPA) Dosing in Restoring Hemodialysis Catheter Function (clinicaltrials.gov) - May 13, 2016
P=N/A, N=150, Recruiting, Sponsor: University of Windsor
Trial primary completion date: Dec 2015 --> Dec 2017 Not yet recruiting --> Recruiting | Phase classification: P4 --> PN/A
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
New P3 trial: PHLO: Pediatric High-Risk Deep Venous Thrombosis Lytic Outcomes Trial (clinicaltrials.gov) - May 10, 2016
P3, N=270, Not yet recruiting, Sponsor: University of Colorado, Denver
- Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment closed, Trial initiation date: Thrombolysis in Ischemic Spinal Cord Stroke (clinicaltrials.gov) - Apr 7, 2016
P2, N=12, Active, not recruiting, Sponsor: Rabin Medical Center
Not yet recruiting --> Recruiting | Phase classification: P4 --> PN/A Not yet recruiting --> Active, not recruiting | Initiation date: Oct 2014 --> Apr 2016
- |||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment open, Trial initiation date, Trial primary completion date: T-TIME: A Trial of Low-dose Adjunctive alTeplase During prIMary PCI (clinicaltrials.gov) - Mar 30, 2016
P2, N=618, Recruiting, Sponsor: NHS Greater Glasgow and Clyde
Not yet recruiting --> Active, not recruiting | Initiation date: Oct 2014 --> Apr 2016 Not yet recruiting --> Recruiting | Initiation date: Dec 2014 --> Mar 2016 | Trial primary completion date: Dec 2016 --> Feb 2018
- ||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment closed, Trial primary completion date: A Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients (clinicaltrials.gov) - Mar 23, 2016
P2a, N=100, Active, not recruiting, Sponsor: Lee Schwamm
Not yet recruiting --> Recruiting | Initiation date: Dec 2014 --> Mar 2016 | Trial primary completion date: Dec 2016 --> Feb 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2016 --> Jul 2016
- || Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
New P3 trial: IMPI-2: IMPI 2 - A Trial of Intrapericardial Alteplase in Large Pericardial Effusion (clinicaltrials.gov) - Feb 4, 2016
P3, N=2176, Recruiting, Sponsor: University of Cape Town